Royalty Report: Drugs, Test/Monitoring, Antibody – Collection: 118864


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Test/Monitoring
  • Antibody
  • Diagnostic
  • Scientific & Technical Instruments
  • Agriculture Forestry & Fishing
  • Aquaculture
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 118864

License Grant
The Licensors and Chilean private non-profit research company, have agreed to supply the Licensee of Germany with antibodies necessary to produce PSP ELISA Test Kit.

Licensors sells to Licensee and Licensee buys from Licensors all transferable rights to use, manufacture and distribute the Licensed Product freely, indicating that these antibodies were developed by Licensors.

License Property
Licensor has developed antibodies against neoSTX and GTXs (Licensed Product).

PSP means paralytic shellfish poisoning for the red tide detection kit.  This antitoxin test system has enabled us to develop a PSP detection test for specific PSP toxins which can be used in specialized laboratories. This method, consistent with our methodology, will extract and analyze acid fluids from a shellfish to detect whether the shellfish contains specific PSP toxins.

Field of Use
Licensee will manufacture and distribute the PSP ELISA Test Kit under the trademark RIDASCREEN, technology with respect to a red-tide detection kit.

IPSCIO Record ID: 113129

License Grant
The Licensor of Chili has agreed to supply the Licensee of Germany with all toxins and conjugates necessary to produce the PSP ELISA Test Kit.

Licensee is interested in obtaining all transferable rights concerning the Licensed Products from Licensor in order to manufacture and to distribute the PSP ELISA Test under the Licensee's trade mark 'RIDASCREEN', co-exclusively, where and how Licensee sees fit, bearing the sole responsibility thereof.

Licensor sells to Licensee and Licensee buys from Licensor all transferable rights to use, manufacture and distribute the Licensed Product freely but indicating that these products were developed and/or obtained by Licensor.

License Property
Licensor has developed technology to isolate neoSTX and GTX and produce their corresponding HRP conjugates (Licensed Products)

The PSP ELISA Test Kit is a paralytic shellfish poisoning (PSP) red tide detection kit.

Field of Use
The tests are done to prevent Human consumption of PSP toxic shellfish may result in death or paralysis in extreme cases.

IPSCIO Record ID: 256630

License Grant
The Chilean Licensor, a private non-profit research company, and Chilean Licensee have agreed to jointly research and work on this project to obtain a system to detect the 'Red Tide Toxin'. Later they will develop a commercial system and bring it to the market.
License Property
Licensor began researching a system to obtain an antidote to the Red Tide toxin through an immunology test. This research has achieved the production of an antitoxin called Saxitoxina that when linked with a Bovine Seroalbumina protein enables the development of an antitoxin test system.

The intellectual property of the antitoxin belongs exclusively to Licensor.

The intellectual and commercial property of the final product will be the common property of the Licensor and the Licensee at 50% each.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.